Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Completed 2Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

CNS 1

Conditions

Fatigue 5Neoplasms 2cyclopia sequence 1Sleep Wake Disorders 1Pain 1Leukemia, Myelogenous, Chronic, BCR-ABL Positive 1Laryngeal Diseases 1Head and Neck Neoplasms 1Glioma 1Central Nervous System Neoplasms 1Carcinoma 1Brain Neoplasms 1

Interventions

Temozolomide 28Radiosurgery 19Radiotherapy 17Bevacizumab 12Magnetic Resonance Spectroscopy 9Radiation 6Erlotinib Hydrochloride 6Carboplatin 6Topotecan 5Nivolumab 5Mental Status and Dementia Tests 5Irinotecan 5Capecitabine 5pembrolizumab 4dabrafenib 4Trastuzumab 4Sunitinib 4Pemetrexed 4Ipilimumab 4Filgrastim 4Cyclophosphamide 4Aminolevulinic Acid 42,2-dimethyl-N-(6-oxo-6,7-dihydro-5H-dibenzo(b,d)azepin-7-yl)-N'-(2,2,3,3,3-pentafluoropropyl)malonamide 4cabozantinib 3Vorinostat 3TPI-287 3Specimen Handling 3Radiotherapy, Intensity-Modulated 3Methylphenidate 3Lomustine 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Terminated × Brain Neoplasms × Modafinil × Clear all
NCT00418691 2020-09-23

Effects of Methylphenidate Versus Sustained Release Methylphenidate on Cognitive Functioning

M.D. Anderson Cancer Center

Phase 3 Terminated
34 enrolled 7 charts
CNS

Brain Neoplasms, Fatigue

Data powered by HemOnc (CC BY 4.0) Colophon âš¡